Description
Improving outcomes in Inflammatory Bowel Disease (IBD) involves early and effective therapy to reduce inflammation and prevent complications. Utilizing biosimilars, which are cost-effective alternatives to biologic medications, can enhance treatment accessibility and adherence. Early intervention with these therapies can lead to better disease control and improved quality of life for patients. Regular monitoring and personalized treatment plans are essential to maximize the benefits of early therapy and biosimilars. Ongoing research and clinical trials continue to support the efficacy and safety of biosimilars in managing IBD.
Résumé
- Sandos' pro-education grant supported a session on improving outcomes in Inflammatory Bowel Disease (IBD) with early, effective therapy and biosimilars. Sandos, a global leader in off-patent medicine, focuses on affordable medicines, biosimilars, and generics, aiming to reduce healthcare costs and improve access. Their portfolio includes about 1,500 biosimilars and generic medicines, contributing significantly to healthcare cost savings.
- The session featured two Crohn's disease cases: a young patient with longitudinal ulcers and a tuberculosis history, treated with Humira and INH therapy, and a woman with fistulizing Crohn's, successfully managed with antibiotics, surgery, and subsequent pregnancy. Discussion topics included the impact of IBD on life, unmet needs in Crohn's and colitis, early use of anti-TNF therapies, and the importance of timing in treatment.
- Adalimumab's efficacy in improving physician and patient-reported outcomes, along with remission rates over six years, was highlighted, based on the PYRAMIDS registry. Studies showed increased adalimumab use over time, with consistent efficacy in continuously treated patients versus those switching between adalimumab and biosimilars. Early biological use in Crohn's is associated with higher remission rates, lower relapse rates, and improved mucosal healing.
- The Crohn's Disease Endoscopic Index (CDEIS) is used to assess disease severity, guiding treatment decisions. Tight control strategies resulted in significantly more patients achieving mucosal healing compared to clinical management alone. Calprotectin levels serve as indicators for treatment optimization, with values above 150 often triggering therapeutic adjustments.
- Switching from reference adalimumab to biosimilars in IBD patients in clinical remission demonstrates comparable efficacy and safety profiles. Research suggests that adalimumab biosimilars are as safe and effective as the originator, supporting wider adoption to reduce healthcare costs without compromising patient outcomes. Multiple studies confirm sustained remission and drug survival rates following the switch between reference drugs and biosimilars.
- The natural history of IBD involves managing flares, with the primary goal of prolonged remission. Success in IBD treatment is defined by reduced costs, improved quality of life, fewer hospitalizations and surgeries, reduced fatigue, improved mood and sleep, increased confidence, and pain reduction. Multi-disciplinary collaboration, involving rheumatologists and gastroenterologists, is essential in managing spondyloarthritis associated with IBD.
Exemple de certificat
À propos des intervenants
Dr. Salem Awadh
Consultant Gastroenterologist, Amrita Medical Center, Abu Dhabi
Commentaires
Commentaires
Vous devez être connecté pour laisser un commentaire.